FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2018

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
HEMATOLOGY
PAPER-III
HEMAT/J/18/48/III
Time: 3 hours
Max. Marks:100
IMPORTANT INSTRUCTIONS
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. Minimal residual disease
What is the basis of MRD?
How does monitoring of MRD in acute leukemia guide the
management?
5+5
2. Describe the uses of flow cytometry:
In benign haematological disorders.
In classifying chronic lymphoproliferative disorders.
5+5
3. Autologous stem cell transplantation:
Describe the procedure.
Enumerate differences from allogenic stem cell
transplantation.
Clinical conditions where this procedure is being used.

4. Targeted therapies:
Which are the hematological conditions where it is in clinical
use?
Describe monitoring of patients in any one condition in
clinical use.
5+5
5. Next Generation Sequencing for Acute Myeloid
Leukemia:
Describe the advantages.
Which molecular changes have prognostic significance?
5+5
6. Non-Hodgkin's lymphoma
Briefly classify the NHLs as per the WHO Classification
2016.
What are the diagnostic tests performed in a patient to
stage the disease?
How is the management monitored on follow up?

7. Hemophilia A and
What is prophylactic therapy?
How is an acute major joint bleed managed?
Carrier detection in hemophilia A.

P.T.O.
FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2018

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
8. Secondary hematological malignancies:
Describe the conditions associated.
Prognosis and management issues which need to be
addressed.
5+5
9. Conditioning regimens for allogenic bone marrow
transplantation:
Enumerate the differences between benign and malignant
disorders.
Peripheral versus bone marrow harvesting.
5+5
10. Chemotherapeutic drugs used in acute lymphoblastic leukemia

Describe the principles of chemotherapeutic drugs being
used in induction phase.
Describe the common toxicities encountered with drugs
used in ALL induction.
5+5